Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19485706 | 0.90 | HDAC1 (0.52) | HDAC1HDAC3ALDH1A1SMN1; SMN2HDAC6 | |
| SCHEMBL2631739 | 0.86 | HDAC1 (0.60) | HDAC1HDAC3ALDH1A1SMN1; SMN2HDAC6 | |
| SCHEMBL22170880 | 0.81 | HDAC3 (0.61) | HDAC1HDAC3ALDH1A1HDAC6CES1 | |
| SCHEMBL10244836 | 0.81 | HDAC3 (0.51) | HDAC1HDAC3ALDH1A1SMN1; SMN2HDAC6 | |
| SCHEMBL30968179 | 0.81 | ALDH1A1 (0.49) | HDAC1HDAC3ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL27284568 | 0.77 | HDAC3 (0.48) | HDAC1HDAC3ALDH1A1HDAC6 | |
| SCHEMBL9331076 | 0.76 | ALDH1A1 (0.48) | HDAC1HDAC3ALDH1A1SMN1; SMN2HDAC6 | |
| SCHEMBL26661152 | 0.74 | CYP1A2 (0.71) | HDAC1HDAC3ALDH1A1SMN1; SMN2HDAC6 | |
| SCHEMBL3504687 | 0.74 | HDAC3 (0.53) | HDAC1HDAC3ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10709105 | 0.74 | HDAC3 (0.47) | HDAC1HDAC3ALDH1A1SMN1; SMN2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796664-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION | 2016-05-05 | — | — | US | disclosed |
| US-9265734-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | REPLIGEN CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | HDAC1, HDAC5, HDAC2 | HDAC1 1/4885HDAC3 5/4885ALDH1A1 194/4885 |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | HDAC1, HDAC5, HDAC2 | HDAC1 1/4885HDAC3 5/4885ALDH1A1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.